CRISPR 制药

CRISPR Therapeutics AG receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 38% discount to our quantitative fair value estimate of $92.33 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's balance sheet increases our valuation estimate. Low leverage mitigates financial risk, potentially boosting a firm's value. For example, the firm's current ratio of 17.8 falls in the top 10% globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.

Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield, a core component of profitability, ranks in the bottom 1% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which, despite our favorable price/fair value ratio, is a negative attribute.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.